Combined intravitreal bevacizumab and triamcinolone injection in a child with Coats disease.
We report a child with Coats disease who demonstrated a rapid response to intravitreal bevacizumab and triamcinolone injection. A 14-year-old boy presented with stage 3A Coats disease unresponsive to initial argon laser treatment and was injected with intravitreal bevacizumab and triamcinolone acetonide. Following intravitreal injection, a superior bullous exudative retinal detachment and subfoveal serous fluid collection dramatically improved. Additional argon laser photocoagulation resulted in complete regression of telangiectatic vessels as well as decrease in macular exudation. Visual acuity improved from 20/400 to 20/125 after treatment, and the boy remained stable 6 months after injection.
Cakir
Mehmet
M
Beyoğlu Eye Training and Research Hospital, Istanbul, Turkey. drmcakir@hotmail.com
Cekiç
Osman
O
Yilmaz
O Faruk
OF
D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004359:Drug Therapy, Combination; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D015861:Retinal Neovascularization / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D013684:Telangiectasis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D042461:Vascular Endothelial Growth Factor A; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide